However, inhibiting MAPK phosphorylation levels in CHF model rats activates the peroxisome proliferator-activated receptor γ (PPAR-γ) pathway by participating in mitochondrial biogenesis, thereby promoting energy generation, improving cardiac energy metabolism, and slowing the pathological progression of CHF (Wang Y. W. et al., 2020). The gene discussed is PPARG; the disease is congestive heart failure.